11 results about "Gabapentin" patented technology

The present invention provides the use of phenylquinolinone and flavonoid derivatives for neuropathic pain, and the phenylquinolinone and flavonoid derivatives include pharmaceutically acceptable salts thereof. The compound of the present invention is a histamine H3 receptor antagonist, which has a different mechanism of action from existing drugs and can be used in the preparation of drugs for treating neuropathic pain diseases. The effect of the compound of the present invention in treating neuropathic pain is better than amitriptyline, gabapentin, pregabalin and carbamazepine, indicating that the compound of the present invention has a better therapeutic effect, has the characteristics of small dosage, good efficacy, high bioavailability and safety, and compared with opioid drugs, the compound of the present invention is not addictive and is a very effective drug for treating neuropathic pain diseases. Therefore, the clinical application prospects are huge. The general structural formula is as follows:

The invention discloses application of Gabapentin in improvement of cognitive impairment of Alzheimer's disease. An application model is an APP / PS1 Alzheimer's disease animal model, a control group is a wild type mouse, Gabapentin granules are dissolved with normal saline and used in an intraperitoneal injection mode, the dosage of single administration is 50 mg / kg, administration is performed for 7 days each month, and then behavioral detection is performed. By detecting and analyzing the actual application result, the effect description of the Gabapentin on the improvement of the AD scene memory is obtained. When the medicine is subjected to intraperitoneal injection and administration, the excessive excitability of neurons can be reduced, the scene memory function of AD mice can be improved, a new use method of Gabapentin is expanded, and a new thought is provided for treatment of AD.

The present invention relates to the technical field of pharmaceutical detection, and particularly relates to an analytical method for the impurity profile of megalol gabapentin besylate raw material drugs. The method uses high performance liquid chromatography with a chiral complexing agent added to the mobile phase for determination. The liquid chromatography conditions are as follows: mobile phase A includes a phosphate-chiral complexing agent buffer solution, mobile phase B includes acetonitrile and water, and gradient elution is adopted; the flow rate is 0.5 - 2.0 mL / min; the chromatographic column stationary phase filler is achiral silane-bonded silica gel; the column temperature is 15°C - 55°C; the detection wavelength is 190 nm - 230 nm. This method has the advantages of simple operation, low cost, good selectivity, high accuracy, and strong universality. It is suitable for the study of the impurity profile of megalol gabapentin besylate raw material drugs, thereby effectively controlling the product quality. At the same time, it can be extended to the study of the impurity profiles of other amino acids and their similar drugs.

The present invention provides methods of treating cannabis withdrawal syndrome and other cannabis related conditions, including cannabis use disorder, in a subject, comprising administering to the subject in need thereof an effective amount of a cannabinoid or an effective amount of a cannabinoid and an effective amount of a second active agent, such as gabapentin or a gabapentin analog.

The present disclosure provides pharmaceutical compositions and methods for the treatment of a sleep disorder such as insomnia, by inducing, extending, or consolidating sleep. The compositions comprise mirtazapine, or a salt or derivative thereof, optionally in combination with and gabapentin, or a salt or derivative thereof, at relatively low doses of each such that the combination provides useful therapeutic benefit while avoiding unwanted side effects associated with treatment using alternative pharmaceutical agents.

Described are room temperature stable gabapentin powders that can be readily reconstituted in water for dosing as an oral solution. The gabapentin powder formulations have improved chemical stability, palatability, portability, storage, and ease of administration, as well as fast reconstitution time, and prolonged product shelf life. The gabapentin powder formulations comprise gabapentin, a sugar alcohol, one or more artificial sweeteners and, optionally, a flavoring agent.

The present disclosure provides pharmaceutical compositions and methods for the treatment of a sleep disorder such as insomnia, by inducing, extending, or consolidating sleep. The compositions comprise mirtazapine, or a salt or derivative thereof, optionally in combination with and gabapentin, or a salt or derivative thereof, at relatively low doses of each such that the combination provides useful therapeutic benefit while avoiding unwanted side effects associated with treatment using alternative pharmaceutical agents.

The invention discloses a biological adhesive tape for nerve stumps after amputation and a preparation method thereof.The biological adhesive tape comprises an outer layer and an inner layer, the outer layer and the inner layer are connected through a layer of PEG-based adhesive, and the outer surface of the outer layer is coated with a PDMS hydrophobic coating; the inner surface of the inner layer is also coated with a PEG-based adhesive layer; wherein the outer layer is prepared from recombinant human-derived I-type collagen and contains dexamethasone drug-loaded microspheres; and the inner layer is prepared from recombinant human I-type collagen and contains gabapentin drug-loaded microspheres. According to the biological adhesive tape, the outer layer inhibits inflammatory reaction and reduces foreign body reaction by slowly releasing glucocorticoid, and the inner layer prevents and relieves neuralgia by slowly releasing gabapentin; the physical fitting effect of the adhesive tape can prevent nerve fibers from growing outwards, so that the risk of neuroma formation is reduced. The biological adhesive tape is high in application flexibility, suitable for nerve stumps with different diameters and shapes and suitable for complex trauma conditions.

A composition for treatment of pain and inflammation in humans includes 4.0-10.0% Diclofenac Sodium by weight, 2.0-6.0% Gabapentin by weight, 1.0-2.0% Baclofen by weight, and 2.0-5.0% Cyclobenzaprine by weight. Other compositions are also disclosed.

Cannabinoid-gabapentinoid conjugates and their formulations possessing dual synergistic pharmacological effects to control neuropathic pain, multiple sclerosis, seizures and postherpetic neuralgia, restless leg syndrome, trigeminal neuralgia, fibromyalgia, diabetic neuropathy, anxiety and bipolar disorders, schizophrenia, sleep disorders, and other related pathological conditions. The conjugates improve the therapeutic potential for both component compounds, while reducing the addiction and substance abuse problems commonly observed with each component, when prescribed independently, thereby providing a solution for cannabinoid and gabapentinoid substance abuse disorders.

The present invention relates to a pharmaceutical composition comprising (a) (i) a combination of Trazodone or a salt thereof, and (ii) Gabapentin or Pregabalin or Milnacian or a salt thereof or a prodrug thereof, and (b) at least one pharmaceutically acceptable excipient, for the treatment of neuropathic pain, wherein the pharmaceutical composition comprises Trazodone:Gabapentin or Pregabalin or Milnacian in a weight ratio of between 1:40 and 1:100, preferably below 1:40 and up to 1:100.